Sample Name
Sample Code
Sample Name
Sample Code
Sample Name
Sample Code
4
Collegium Pharmaceutical
COLL
5
Enerpac Tool
EPAC
(FY)Dec 31, 2024 | (Q4)Dec 31, 2024 | (Q3)Sep 30, 2024 | (Q2)Jun 30, 2024 | (Q1)Mar 31, 2024 | (FY)Dec 31, 2023 | (Q4)Dec 31, 2023 | (Q3)Sep 30, 2023 | (Q2)Jun 30, 2023 | (Q1)Mar 31, 2023 | |
---|---|---|---|---|---|---|---|---|---|---|
Operating cash flow (Indirect Method) | ||||||||||
Cash flow from continuing operating activities | -53.40%14.74M | 2.40%5.45M | -53.57%4.47M | -85.04%1.17M | -58.76%3.64M | -5.70%31.63M | -50.11%5.33M | 8.20%9.63M | 17.83%7.85M | 20.80%8.83M |
Net income from continuing operations | -137.54%-9.98M | -414.11%-16.17M | -95.84%264K | -62.31%2.62M | -59.45%3.31M | -0.33%26.59M | -32.09%5.15M | -18.12%6.34M | 17.17%6.95M | 50.30%8.15M |
Operating gains losses | 60.47%-51K | ---50K | 73.33%-24K | --10K | 133.33%13K | -178.66%-129K | --0 | -142.65%-90K | --0 | 9.30%-39K |
Depreciation and amortization | 68.82%4.63M | 110.10%1.73M | 59.47%1.03M | 57.34%1.01M | 36.62%873K | 6.44%2.75M | 14.01%822K | 4.89%644K | 5.09%640K | 0.63%639K |
Deferred tax | -2,270.68%-4.53M | -946.62%-4.49M | -1,782.35%-960K | 244.00%432K | -16.81%490K | 78.64%-191K | 48.62%-429K | 81.11%-51K | -35.75%-300K | 36.34%589K |
Other non cashItems | -88.12%-792K | -88.07%-205K | -138.82%-203K | -169.01%-191K | -23.72%-193K | 37.72%-421K | 29.22%-109K | 62.39%-85K | 54.78%-71K | -12.23%-156K |
Change in working capital | -254.91%-3.87M | 165.00%754K | -61.78%751K | -573.91%-4.03M | -3.40%-1.34M | -253.38%-1.09M | -178.97%-1.16M | 1,236.73%1.97M | -10.54%-598K | -255.07%-1.3M |
-Change in receivables | 138.49%1.08M | 80.60%-234K | 191.29%839K | -130.87%-1.19M | 1,120.25%1.66M | -50.62%-2.8M | 6.44%-1.21M | 4.27%-919K | -54.65%-515K | -122.61%-163K |
-Change in other current assets | -197.60%-4.79M | -148.08%-5.02M | 228.79%7.4M | -3.25%-2.54M | -272.40%-4.63M | 121.92%4.91M | 133.48%10.43M | 43.33%-5.75M | 85.56%-2.46M | 742.63%2.69M |
-Change in other current liabilities | 95.31%-150K | 157.81%6M | -186.77%-7.49M | -112.52%-298K | 142.69%1.63M | -112.80%-3.2M | -507.37%-10.39M | -23.26%8.63M | -85.87%2.38M | -171.96%-3.82M |
Cash from discontinued operating activities | ||||||||||
Operating cash flow | -53.40%14.74M | 2.40%5.45M | -53.57%4.47M | -85.04%1.17M | -58.76%3.64M | -5.70%31.63M | -50.11%5.33M | 8.20%9.63M | 17.83%7.85M | 20.80%8.83M |
Investing cash flow | ||||||||||
Cash flow from continuing investing activities | 6.48%-122.28M | -48.99%-42.67M | 98.17%-822K | -188.91%-55.48M | 38.53%-23.3M | 42.84%-130.75M | 32.60%-28.64M | 21.12%-45M | 28.91%-19.2M | 62.91%-37.9M |
Net investment purchase and sale | -1,581.22%-3.58M | -42.15%-3.76M | 128.10%958K | -176.74%-1.24M | 19.04%469K | -100.88%-213K | -102.73%-2.65M | 101.81%420K | 107.20%1.62M | 101.44%394K |
Net proceeds payment for loan | 11.81%-112.9M | -54.90%-38.26M | 100.36%157K | -152.86%-52.66M | 42.70%-22.14M | 46.82%-128.03M | 81.43%-24.7M | -39.66%-43.86M | -405.85%-20.83M | 46.51%-38.64M |
Net PPE purchase and sale | -94.02%-714K | 257.14%11K | -110.77%-137K | 68.63%-64K | -469.57%-524K | 67.29%-368K | 98.63%-7K | 22.62%-65K | 12.82%-204K | 68.92%-92K |
Net intangibles purchase and sale | 11.40%-4.88M | 48.91%-656K | -51.40%-1.68M | 11.31%-1.51M | 26.67%-1.03M | 17.25%-5.51M | 32.10%-1.28M | 51.91%-1.11M | -62.57%-1.71M | 0.21%-1.41M |
Net other investing changes | -105.91%-199K | --0 | 67.88%-124K | --0 | -104.08%-75K | 178.33%3.37M | 100.02%1K | ---386K | 112.44%1.91M | 294.19%1.84M |
Cash from discontinued investing activities | ||||||||||
Investing cash flow | 6.48%-122.28M | -48.99%-42.67M | 98.17%-822K | -188.91%-55.48M | 38.53%-23.3M | 42.84%-130.75M | 32.60%-28.64M | 21.12%-45M | 28.91%-19.2M | 62.91%-37.9M |
Financing cash flow | ||||||||||
Cash flow from continuing financing activities | 141.77%200.73M | -23.02%12.81M | 134.14%137.01M | 118.14%21.03M | -75.86%29.89M | -64.30%83.03M | -71.14%16.65M | 16.48%58.51M | -645.29%-115.94M | 19.72%123.8M |
Increase decrease in deposit | 27.96%221.67M | 380.93%14.13M | 54.01%138.31M | 158.16%22.63M | -60.96%46.61M | 71.65%173.24M | 107.16%2.94M | 66.93%89.81M | -159.68%-38.9M | 419.56%119.4M |
Net issuance payments of debt | 82.35%-15M | --0 | ---15M | 114.19%15M | -363.34%-15M | -159.60%-85M | -85.00%15M | --0 | -164.24%-105.7M | -93.11%5.7M |
Net commonstock issuance | -1,602.33%-732K | ---13K | --0 | -597.67%-300K | ---419K | 99.38%-43K | --0 | --0 | 98.57%-43K | --0 |
Cash dividends paid | -0.68%-5.2M | -0.54%-1.3M | -0.54%-1.3M | -0.70%-1.3M | -0.93%-1.3M | -27.96%-5.17M | -0.70%-1.29M | -41.82%-1.29M | -40.74%-1.29M | -39.42%-1.29M |
Cash from discontinued financing activities | ||||||||||
Financing cash flow | 141.77%200.73M | -23.02%12.81M | 134.14%137.01M | 118.14%21.03M | -75.86%29.89M | -64.30%83.03M | -71.14%16.65M | 16.48%58.51M | -645.29%-115.94M | 19.72%123.8M |
Net cash flow | ||||||||||
Beginning cash position | -12.32%114.51M | 91.54%232.11M | -6.71%91.46M | -44.64%124.74M | -12.32%114.51M | 40.13%130.6M | 15.71%121.18M | -4.49%98.04M | 121.48%225.33M | 40.13%130.6M |
Current changes in cash | 679.32%93.2M | -265.91%-24.41M | 507.79%140.66M | 73.85%-33.28M | -89.20%10.23M | -143.01%-16.09M | -125.79%-6.67M | 1,009.93%23.14M | -14,134.51%-127.29M | 1,008.91%94.73M |
End cash position | 81.38%207.71M | 81.38%207.71M | 91.54%232.11M | -6.71%91.46M | -44.64%124.74M | -12.32%114.51M | -12.32%114.51M | 15.71%121.18M | -4.49%98.04M | 121.48%225.33M |
Free cash flow | -65.07%8.95M | 17.95%4.76M | -68.53%2.63M | -107.45%-442K | -72.55%2M | -0.52%25.63M | -51.23%4.03M | 28.47%8.37M | 10.42%5.94M | 30.14%7.29M |
Currency Unit | USD | USD | USD | USD | USD | USD | USD | USD | USD | USD |
Accounting Standards | US-GAAP | US-GAAP | US-GAAP | US-GAAP | US-GAAP | US-GAAP | US-GAAP | US-GAAP | US-GAAP | US-GAAP |
Audit Opinions | Unqualified Opinion with Explanatory Notes | -- | -- | -- | -- | Unqualified Opinion with Explanatory Notes | -- | -- | -- | -- |